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Abstract
Mesenchymal stem cells (MSCs) are multipotent stromal cells with a strong potential in
human regenerative medicine due to their ability to renew themselves and differentiate
into  various  specialized  cell  types  under  certain  physiological  or  experimental
conditions. MSCs secrete a broad spectrum of autocrine and paracrine factors (MSCs’
secretome) that could exert significant effects on cells in their vicinity. MSCs have been
clinically tested and have displayed a great potential in the treatment of bone/cartilage
fractures and disorders, diabetes, cardiovascular diseases and immune, neurodegener‐
ative  and  inflammatory  diseases.  The  therapeutic  efficacy  of  MSCs  was  initially
attributed to their multipotent character and ability to engraft and differentiate at the
site of injury. However, in recent years, it has been revealed that either undifferentiated
or differentiated MSCs’ secretome plays an important role in the therapeutic potential
of MSCs. The deciphering of the composition of MSCs’ secretome through proteomic
and metabolic analyses and implementation of certain advanced analytical (nuclear
magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), chromatography,
etc.)  and  immunological  methods  could  contribute  to  the  understanding  of  the
mechanisms underlying the therapeutic effects of MSCs.
Keywords: secretome, mesenchymal stem cells, proteomics, metabolomics, umbilical
cord blood plasma, growth factors
1. Introduction
Mesenchymal stem cells (MSCs) are one of the most promising types of stem cells for cell‐
based therapies. The continuously increasing interest in the therapeutic application of MSCs
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to various diseases can be linked to their capacity to self‐renew and differentiate into several
cell types, to secret soluble factors with paracrine actions and their immunosuppressive and
immunomodulatory properties [1–5]. In addition, MSCs can be easily isolated from a wide
range of ethically acceptable adult tissues and demonstrate a significant capacity for ex vivo
expansion [6, 7].
Mesenchymal stem cells (MSCs) were first isolated and described by Friedenstein et al. in the
early 1970s as a population of multipotent cells found in the bone marrow that can differentiate
into osteocytes, chondrocytes, adipocytes and myoblasts [8, 9]. Currently, MSCs can be found
and isolated from various foetal and adult tissues including bone marrow, adipose tissue,
skeletal muscle, umbilical cord blood (UCB), umbilical cord tissue or matrix (UCT, Wharton's
jelly), peripheral blood, dental pulp and amniotic fluid [10–12]. Despite their presence in
different tissue sources, the isolated MSCs exhibit a similar characteristic phenotype [2] with
some additional features that reflect their tissue of origin [13].
MSCs are able to renew themselves and differentiate into various specialized cell types such
as bone, cartilage, muscle and fat cells under certain physiological or experimental conditions
and may serve as a renewable source of cell and tissue replacements [1, 2]. According to the
definition agreed by the International Society for Cellular Therapy (ISCT) in 2006, mesenchy‐
mal stem cells are characterized by (a) their capacity to adhere to plastic; (b) their expression
of specific surface markers, namely, CD73, CD90 and CD105, and no expression of CD14, CD19,
CD34, CD45 and HLA‐DR. Additionally, according to the ISCT, MSCs are able to undergo tri‐
lineage differentiation into adipocytes, chondrocytes and osteoblasts [2].
Besides their multipotency, MSCs possess unique characteristics, such as the ability to migrate
to sites of injury, inflammation or cancer, the capacity to secrete a broad spectrum of autocrine/
paracrine factors that could exert significant effects on cells in their vicinity and the ability to
modulate inflammatory and regenerative processes and the immune system. MSCs have been
clinically tested for treatment of a variety of pathologies and diseases such as brain paralysis,
cardiovascular diseases and myocardial infarction, type I diabetes, multiple sclerosis, Crohn's
disease, bone fractures, graft versus host disease (GVHD) in bone marrow transplantation,
osteoarthritis and rheumatoid arthritis [3, 14, 15].
The therapeutic effects of MSCs were initially attributed to the ability to migrate to sites of
injury and inflammation, engraft into the damaged tissues and differentiate into specialised
cell types. However, many studies provide strong evidences that the therapeutic efficacy of
transplanted MSCs is not dependent on the physical proximity of the transplanted cells to the
damaged tissue and propose that MSCs exert their therapeutic activity through MSCs’
secretome [16, 17]. Although these studies, and many others, indicate the potency of MSC‐
secreted factors in mediating tissue repair and regeneration, the mechanisms of MSCs’ action
are not completely clear. The scientific community has tried to understand MSCs’ biological
mechanisms of action considering their capacity to secret soluble factors with paracrine actions
and unveil their potential in cell therapy and regenerative medicine.
Proteomics and metabolomics are omics techniques that employ state of the art analytical
instrumentation in conjunction with pattern recognition techniques for comprehensive and
Metabolomics - Fundamentals and Applications44
simultaneous systematic analysis of biological systems and monitoring of cellular and systemic
proteomic and metabolic fluctuations in response to xenobiotic exposure, environmental
factors, physiological stimuli and genetic modifications [18–23].
The studies of the composition of secretion products of MSCs through proteomic and metabolic
analyses could contribute to the understanding of the mechanisms underlying the therapeutic
effects of MSCs. Currently, certain advanced analytical (nuclear magnetic resonance (NMR)
spectroscopy, mass spectrometry (MS), chromatography, immunological assays, etc.) and
chemometric techniques exist for proteomic and metabolic analyses of bio‐fluids, which can
be applied in MSC secretomics [20, 22–24].
2. MSCs’ conditioned medium and secreted products
The paracrine effect of MSCs and their ability to synthesise and secrete a broad spectrum of
growth factors, chemokines and cytokines that could exert significant effects on cells in their
vicinity were first described by Haynesworth et al. [25]. This study was followed by other
publications in the scientific literature describing therapeutic effects of these secreted factors
[26, 27].
The MSCs’ secreted factors are principal molecules for intercellular communication involved
in most physiological processes, such as cell signalling, differentiation, invasion, metastasis,
cell adhesion and binding, angiogenesis and apoptosis [18]. Growth factors, extracellular
matrix proteins and extracellular matrix remodelling enzymes, pro‐inflammatory, anti‐
inflammatory and pleiotropic cytokines, chemokines and angiogenic factors have been
recently identified in stem cell secretomes including MSCs’ one [19].
The compounds synthesised in the process of the proliferation and differentiation of MSCs
could be secreted from the cells either constitutively or in the regulated manner and determine
the composition of the extracellular environment [28]. Cell treatments in vitro could initiate
alterations in the amount of particular factors secreted in the culture media [29, 30]. The
secreted molecules could act as a possible replacement of stem cells for therapeutic applications
that allow precise dosing, low biological variability and overcome of several stem cell related
issues including cell origin and immunocompatibility [20]. The therapeutic application of
MSCs’ secretome could reveal new safe and effective strategies with predictable outcomes as
an alternative to the cell therapy.
2.1. Preparation of MSCs’ conditioned medium samples
MSCs’ secretome studies involve a number of defined stages: (i) cell isolation and characteri‐
sation; (ii) cell culture in an appropriate culture medium; (iii) cell expansion and differentiation
and (iv) collection of conditioned media.
The preparation of MSCs’ conditioned medium has been performed by our research
group and published elsewhere and here it is resumed and described [31]. Different
batches of human MSCs from Wharton's jelly umbilical cord cryopreserved cells are in
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vitro cultured and maintained in a humidified atmosphere with 5% CO2 at 37°C. This
process can be applied to previously isolated, expanded and cryopreserved MSCs from a
diversity of tissues, with the advantage of a higher number of MSCs obtained in a shorter
culture time, not dependent on donor's availability and ethic committee's authorization.
During expansion, the cells become long spindle‐shaped, and their phenotype is con‐
firmed by flow cytometry analysis for a comprehensive panel of markers, such as platelet
endothelial cell adhesion molecule‐1 (PECAM‐1, CD31), homing cell adhesion molecule
(HCAM, CD44), CD45 and Endoglin (CD105). Characterization is also performed with the
following antibodies and their respective isotypes: PE anti‐human CD105; APC anti‐hu‐
man CD73; PE anti‐human CD90; PerCP/Cy5.5 anti‐human CD45: FITC anti‐human CD34;
PerCP/Cy5.5 anti‐human CD14; Pacific Blue anti‐human CD19 and pacific‐blue anti‐hu‐
man HLA‐DR. The karyotype of the MSCs should also be determined to ensure that no
structural alterations are found, which demonstrate the absence of neoplastic characteris‐
tics in these cells, as well as chromosomal stability of the somatic and sexual chromo‐
somes due to the cell culture procedures. Two mesenchymal stem cell media have been
tested for the conditioning, namely, PromoCell® medium (LabClinics, Promocell, C‐28010,
so‐called commercial medium further on) and Dulbecco's Modified Eagle Medium
(DMEM, Gibco®) supplemented with 10% of foetal bovine serum (FBS, Gibco®), 2 mM
glutamine (sigma), 100 U/ml of penicillin and 100 µg/ml of streptomycin (Sigma). Condi‐
tioned medium (CM) is normally collected from passage 4 (P4) MSCs. To obtain the de‐
sired CM, 4000 cell/cm2 are plated and allowed to grow until reaching a minimum of 80%
confluence. At this stage, the commercial medium is removed from the T‐flasks, and after
five washing cycles with Dulbecco's Phosphate Buffered Saline 1× (DPBS) without calcium
(Ca2+) and magnesium (Mg2+) (Gibco®), Dulbecco's Modified Eagle Medium/Nutrient Mix‐
ture (DMEM, Gibco®) supplemented with 100 U/ml of penicillin and 100 µg/ml of strepto‐
mycin (Sigma) is added. The cell culture T‐flasks are maintained in a humidified
atmosphere with 5% CO2 at 37°C, allowing the adherent cells to be in contact with a se‐
rum‐free basal medium. The culture medium, added after the confluence is reached, is not
renewed and it is collected at different time points (24 and 48 h). For conditioning with
Dulbecco's Modified Eagle Medium/Nutrient Mixture (DMEM, Gibco®) supplemented
with 100 U/ml of penicillin and 100 µg/ml of streptomycin (Sigma), samples of the medi‐
um are also collected at 24 and 48 h. Upon collection, the CM is frozen at –20°C, being
later on thawed on the day of the experiments. 1H‐NMR spectra and Multiplexing LASER
Bead analysis were acquired from both 24 and 48 h samples.
3. Human umbilical cord blood plasma as a potential supplement for
MSCs’ culture and conditioning
In search of a suitable alternative (and animal‐component‐free) culturing medium for the
referred MSCs, we employed similar analytical techniques in order to better characterize
hUCBP and assess its viability as a substitute for standard usage in FBS. The utilization of FBS
in cellular culture has a series of ethical, technical and biological issues that made challenging
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its most extended usage in clinical setting. Since exogenous protein and other factors’ supple‐
mentation is still a facilitating point in MSCs’ expansion (as chemically defined media are
mostly expensive and occasionally underperforming), research has focused on finding suitable
replacements for the FBS [31–34].
3.1. Preparation of hUCBP samples
These samples were collected from different consenting donors that clinically evaluated
according to the Portuguese law 12/2009 (Diário da República, lei 12/2009 de 26 de Março de
2009) and analysed by flow cytometry and for microbiological contamination for aerobic and
anaerobic microorganisms and fungi.
Umbilical cord blood (UCB) was collected from the umbilical vein by gravity into a 150 ml
volume simple bag (reference 1385.13, Suru, Portugal), containing 21 ml of citrate‐phosphate‐
dextrose (CPD), and stored at 4 ± 2°C until processing for cryopreservation. UCB samples were
transported to the laboratory at refrigerated temperatures ranging between 4 and 22°C, within
48 h after collection. The collected UCB is subjected to a volume reduction process using
AXP system® (thermogenesis). During the two‐step centrifugation, whole blood is separated
into three layers that are delivered into a red blood cell (RBC) bag and a freezing bag. Plasma
remains in the processing bag which is also known as plasma bag. Samples of the UCB are
taken by sampling pillows integrated within the kit for flow cytometry analysis. The total
nucleated cell (TNC) count, CD34+ cell counts, CD34+ cell viability and leucocyte (CD45+)
viability are determined by samples obtained from the UCB before volume reduction.
Microbiological controls are usually performed after volume reduction and before cryopre‐
servation and tested for microbiological contamination using an automated blood culture
system (BacT/ALERT®, bioMérieux) at 35°C for 14 days. TNC and the number of white blood
cells (WBC) are counted with a haematology autoanalyser (Ac T diff2™, Beckman Coulter,
Inc.). The CD34+ cell number and the CD34+ viability are quantified by flow cytometry (BD
FACSCalibur™ 3 CA Becton Dickinson, BD Biosciences); the software for acquisition and
analysis was BD CellQuest™ and BDCellQuest™ Pro Templates, respectively. The clusters of
differentiation (CD) were used to enumerate the total number of CD34+ cells and the total
number of leucocytes (CD45+), and the 7‐amino‐actinomycin D (7AAD) nucleic acid dye was
used for viability measure (BD Stem Cell Enumeration kit, Becton Dickinson, BD Biosciences),
according to the manufacture's protocol. The BD stem cell enumeration simultaneously
enumerates the total viable dual‐positive (CD45+/CD34+) haematopoietic stem cells in absolute
counts of CD34+ cells per µl and the percentage (%) of viable leucocytes (CD45+) that are CD34
positive (CD34+).
The sample collection, sample storage and sample preparation are very important steps in
proteomics and metabolomics. If the samples are not collected properly or the samples are not
stored or processed uniformly, the metabolomics data generated from these samples could be
invalid. Hence, the sample collection, storage and processing procedures are critical for
conducting successful metabolomics studies.
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4. Proteomic techniques
Proteomics is the omics technique that focuses on proteins and their functions in biological
systems. Proteins are involved in all processes of living organisms and possess a complex
structure, interactions, dynamics in concentration, degradation and/or modification which are
the key factors defining the behaviour of biological systems. Therefore, the main goal of
proteomics is the identification, quantification and characterisation of the protein content of
biological samples, such as organs, tissues, cells and biological fluids [22].
Well‐established methodologies exist for proteomic analysis of bio‐fluids that include separa‐
tion and protein identification techniques, and chemometric methods for data interpretation
and visualization [18, 20, 24]. The extensive development of advanced analytical techniques
and instrumentation in the last decade has enabled the proteomic analysis of cell secretome
and several profiles from different cell types, body fluids and physiological conditions that
have been studied and established [20, 35]. The continuously increasing interest in secretome
proteomics has been raised due to the pivotal role of these secreted proteins in all physiological
processes in living systems, including physiological, pathophysiological and genetic transfor‐
mations, degenerative processes, disease conditions and progression [23, 24, 28].
4.1. Proteomic analysis of MSCs’ secretome
The proteomic profiling of biological systems, including cell secretomes is mainly centred on
mass spectrometry (MS), chromatography (liquid chromatography, LC), immunological
assays and chemometric techniques [20, 24]. In vivo and ex vivo studies of MSCs’ secretome
encounter significant technical difficulties due to the low abundance of secreted proteins
relative to total proteins in tissue/bio‐fluid, the presence of different cell types including the
cells of interest, endothelial cells and fibroblast cells, possibility of contamination by blood and
the difficulty of accessing the extracellular medium in a tissue section [20, 23]. Therefore, in
vitro strategies have been developed to probe the secretome under physiological conditions,
where culture medium is conditioned by cells for a certain period of time followed by
collection, preparation and processing of the medium for proteomic analysis. The proteomic
analysis of MSCs’ secreted products involves MSCs’ isolation and characterisation; culture
medium preparation; MSCs’ conditioning; isolation of the conditioned medium; implemen‐
tation of appropriate proteomic analytical techniques and protocols and data analysis.
Proteomic studies of MSCs’ secretome are currently performed under in vitro conditions as
shown in Figure 1 [20, 23].
Proteomic analysis based on LC, MS, LC‐MS, immunological assays and bioinformatics has
already been applied in the studies of protein and peptide separation, identification and
quantification, screening of posttranslational modifications and characterisation of secreted
products [20, 22, 23, 36, 37]. Proteomic studies performed on MSCs’ secretome have been
recently revised considering the cell origin, conditioning protocols and the analytical techni‐
ques used [20]. The studies of the secreted products of MSCs isolated from various foetal and
adult tissues including bone marrow, adipose tissue, skeletal muscle, umbilical cord blood and
umbilical cord tissue have been performed. Proteomic profiles of secreted products obtained
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from culturing of a wide range of human and animal MSCs have been established through
implementation of proteomic analytical techniques such as MS, LC, LC/MS, immunological
assays and bioinformatics [20, 38–42].
Figure 1. Schematic representation of the steps followed in a proteomic analysis of conditioned medium obtained from
MSCs’ in vitro expansion.
We have recently disclosed proteomic study of several MSCs’ conditioned media based on
Multiplexing LASER Bead Technology which enable the simultaneous testing of numerous
analytic categories such as cytokines, chemokines and growth factors in a single assay [31].
Human Primary Cytokine Array/Chemokine Array 41‐Plex Panel (Eve Technologies, Calgary,
Alberta, Canada) has been performed to analyse the conditioned media, including the
following cytokines, chemokines and growth factors: epidermal growth factor (EGF), eotaxin‐
1, fibroblast growth factor 2 (FGF‐2), fms‐related tyrosine kinase 3 ligand (Flt‐3L), fractalkine,
granulocyte colony‐stimulating factor (G‐CSF), granulocyte macrophage colony‐stimulating
factor (GM‐CSF), GRO(pan), interferon‐ alpha 2 (IFNα2), interferon‐gamma (IFNγ), several
interleukins (IL‐1α, IL‐1β, IL‐1ra, IL‐2, IL‐3, IL‐4, IL‐5, IL‐6, IL‐7, IL‐8, IL‐9, IL‐10, IL‐12 (p40),
IL‐12 (p70), IL‐13, IL‐15, IL‐17A), interferon gamma‐induced protein 10 (IP‐10), monocyte
chemotactic protein‐1 (MCP‐1), monocyte chemotactic protein‐3 (MCP‐3), macrophage‐
derived chemokine (MDC), macrophage inflammatory protein‐1 alpha (MIP‐1α), macrophage
inflammatory protein‐1 beta (MIP‐1β), platelet‐derived growth factor‐AA (PDGF‐AA),
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platelet‐derived growth factor‐AB/BB (PDGF‐AB/BB), chemokin (C‐C motif) ligand 5
(RANTES or CCL5), soluble CD40 ligand (sCD40L), transforming growth factor alpha
(TGFα), tumour necrosis factor alpha (TNFα), tumour necrosis factor beta TNFβ and vascular
endothelial growth factor A (VEGF‐A). TGF‐β 3‐Plex Array Multi‐Species (Eve Technologies,
Calgary, Alberta, Canada) was also performed to analyse the tumour growth factor beta 1, 2
and 3 (TGF‐β 1, 2 and 3).
Figure 2. Proliferative and antiapoptotic growth factors, immunomodulatory, immunosupressive cytokines and che‐
mokines concentrations in unconditioned (Com. Medium* and DMEM) and conditioned media (24/48 h Com. Medium
and DMEM). (Multiplexing LASER Bead Analysis (Eve Technologies, Calgary, Alberta, Canada). *Commercial medium
from PromoCell (LabClinics, Promocell, reference C‐28010), adapted from [31].
The results from the Human Primary Cytokine Array/Chemokine Array 41‐Plex Panel together
with the TGF‐β 3‐Plex Array allowed the comprehensive analysis of the cytokines, chemokines
and growth factors included in conditioned media in comparison with unconditioned culture
media [43]. It was confirmed that the concentration of important proliferative and anti‐
apoptotic factors increases the process of cell conditioning. This was particularly evident for
TGF‐β1, EGF, G‐CSF, GM‐CSF, PDGF‐AA and VEGF. Some of these factors like EGF were even
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absent in unconditioned media. It was also confirmed that the content of factors such as TGF‐
β1 and G‐CSF depends on the duration of the conditioning process (Figure 2).
4.2. Proteomic analysis of hUCBP
Following an identical analytical protocol hUCBP depicted impressively high detection levels
for TGF‐β family members 1–3. Fair concentrations of other factors like VEGF, PDGF‐AA,
PDGF‐BB and EGF were also observed. Other immunossupressive/immunomodulatory
factors can also be found at interesting levels in hUCBP (Figure 3).
Figure 3. Proliferative and anti‐apoptotic growth factors (A), immunomodulatory, immunosuppressive cytokines (B)
and chemokines (C) concentrations in UCB Plasma and unconditioned media (Com. Medium* and DMEM). (Multi‐
plexing LASER Bead Analysis (Eve Technologies, Calgary, Alberta, Canada). *Commercial medium from PromoCell
(LabClinics, Promocell, C‐28010), as in [31].
5. Metabolomics techniques
Metabolomics is a powerful approach for multicomponent analysis of biological samples that
allow the comprehensive and simultaneous systematic profiling of multiple metabolite
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concentrations and their cellular and systemic fluctuations in response to xenobiotic exposure,
environment, stimuli and genetic modulations. Metabolomics is important and well‐estab‐
lished technique that encompasses the multicomponent analysis of metabolites in biological
fluids, tissue and cell extracts using advanced analytical techniques [21, 43–46].
Figure 4. Schematic representation of the steps followed in a metabolomic analysis of conditioned medium obtained
from MSCs’ in vitro expansion.
An analysis of the metabolite spectrum in a biological system provides a detailed information
and specific view into cellular metabolic processes under normal and altered conditions. The
study of the entire multicomponent metabolic profile of biological systems is a challenging
task and relies on the use of reproducible analytical technologies that provide sufficiently high
sensitivity, high resolution and wide dynamic range. Metabolomics is mainly based on NMR
spectroscopy (NMR) and mass spectrometry (MS), with chromatographic separation usually
involved in the latter [43–46]. Both spectroscopic techniques could give valuable information
on the structure and quantitative distribution of metabolites in biological systems.
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Metabolomics studies usually result in large number of complex multivariate data sets that
are typically analysed using chemometric and bioinformatics methods for data interpretation
and visualization. These studies have been extensively expanded after implementation of
pattern recognition (PR), expert systems and related bio‐informatics tools to interpret and
classify complex metabolic data sets. Well‐established methodologies and protocols for
metabolic analysis of biological samples have been extensively developed [21, 43–48].
The metabolomics analysis of biological samples involves several basic steps (Figures 1 and
4): sample collection; sample manipulation and storage; sample preparation for metabolic
analysis; application of appropriate analytical method(s); data acquisition; data analysis
(metabolites identification and quantification) and pattern recognition of spectral data (data
interpretation and visualisation).
The development of advanced analytical techniques and instrumentation in the last decades
has enabled a comprehensive metabolic analysis of diverse and complex biological samples,
such as tissues, cells, tissues and cellular extracts, bio‐fluids, etc. Certain advanced analytical
techniques such as NMR, MS, LC, LC‐MS and bioinformatics exist for metabolic analysis of
biological systems, which can be applied in MSC secretomics [21, 43–48].
Studies of the composition of MSCs’ secretome could contribute to the understanding of the
mechanisms underlying the therapeutic effects of MSCs and assessment of the potential of
MSCs’ secretome as an alternative to MSCs’ cell therapy.
5.1. Metabolic analysis of MSCs’ secretome by NMR spectroscopy
NMR spectroscopy being a high reproducible and quantitative analytical technique, with
minimal or no sample preparation and the sample can be recovered following the analysis, is
one of the main tools for metabolic profiling, identification and quantification of known and
unknown metabolites in biological samples. It offers unique opportunities for improving the
structural and functional characterization of metabolome, which can be essential for the
understanding of many biological processes and physiological changes in biological systems
[43–48].
NMR spectroscopy as a quantitative non‐destructive, non‐invasive analytical technique can
be used effectively to screen for metabolite profiles and to monitor structural and physiological
changes in biological systems [21, 43, 44]. Nowadays, high‐resolution NMR spectroscopy is
one of the most powerful analytical techniques available for metabolic profiling of biological
systems and could be suitable for metabolic analysis of MSC secretome. One of the advantages
of NMR spectroscopy over other methods is that it can generate a large quantity of information
concerning the metabolic composition of samples, making possible the simultaneous identi‐
fication and quantification of structurally diverse metabolites, without the need for individual
isolation or no special sample preparation [43, 44].
5.1.1. Samples collection and preparation
As for the proteomic analysis, the sample collection, storage and processing procedures are
critical for conducting successful metabolomics studies. As previously studied, the collected
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samples of CM or for other biological fluids like umbilical cord blood plasma [31] should be
centrifuged to remove cellular detritus and stored at –20 or even –80°C. The cellular systems
used in the metabolomics and secretome profile studies should be previously characterised,
including the flow cytometry or immunecitochemistry profile and karyotype.
At the end of the cell conditioning period, the conditioned medium is collected and centrifu‐
gation and/or filtration are usually applied to remove cell residues. In some cases, larger
volumes of conditioned medium can be concentrated to succeed optimal experimental
conditions. Upon collection and purification, the conditioned medium can be frozen and stored
at –20°C, being later on thawed on the day of the NMR experiments.
The preparation of samples for NMR analysis can involve the addition of buffer to stabilize
the pH, deuterated water (D2O) as a magnetic field lock signal and reference compound to be
used as a chemical shift and quantitation standard. The reference compound used in aqueous
media is usually sodium trimethylsilyl‐[2,2,3,3‐d4]‐propionate (TSP), which can be used as an
internal or external standard. Absolute concentrations of metabolites can be obtained by the
use of internal standard of known concentration added to the sample.
5.1.2. NMR techniques
The metabolomic study of bio‐fluids is usually based of 1H NMR spectroscopy. The NMR data
for all samples need to be acquired and processed uniformly. The NMR experimental condi‐
tions and procedures are critical for conducting successful metabolomics studies and need to
be uniform. The large interfering NMR signal arising from water in all bio‐fluids can be
eliminated by the use of standard NMR solvent suppression pulse sequences. 1H NMR spectra
using a 1D NOESY (noesygppr1d) pulse sequence (recycle delay‐90°‐t1‐90°‐tm‐ acquire) and
a Carr‐Purcell‐Meiboom‐Gill (CPMG, cpmgpr1d) pulse sequence (recycle delay‐90°‐[τ‐180°‐
τ]n‐ acquire) can be acquired. The 1D NOESY experiment generates spectra with improved
solvent peak (at 4.70 ppm) suppression. Relaxation edited 1H NMR spectra with T2 (spin‐spin
relaxation time) filter using CPMG pulse sequence and suppression of water resonance were
acquired to facilitate the identification of low molecular weight metabolites, reducing signals
from high molecular weight species or systems in intermediate chemical exchange. The
generated NMR data should be processed spectra were processed uniformly.
5.1.3. NMR data analysis
NMR spectra of biological systems are usually extremely complex because of the large number
of components in the samples, resulting in spectra with complex line shapes and significant
overlap of the resonance signals. The analysis of NMR spectra and identification of the
metabolites in biological samples may involve a number of spectral techniques, information
from databases of known metabolite spectra and NMR assignment software. Though very
complex, the NMR spectra of biological samples (in particular 1H NMR) allow direct assign‐
ment of resonance signals of some metabolites based on their chemical shifts, multiplicity and
intensity and spectral analysis of appropriate NMR spectroscopic techniques such as two (2D)
or multidimensional NMR techniques. 2D NMR spectroscopy can be useful to increase the
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signal dispersion in spectra with significant overlap of the resonances and reveal the connec‐
tivity between signals (1H/1H Correlation spectroscopy (COSY); 1H/1H Total Correlation
spectroscopy (TOCSY), 1H/13C or 1H/15N Hetero‐correlation spectroscopy (HSQC, HMBC))
and/or to define the multiplicity and coupling pattern of resonances (2D J‐resolved spectro‐
scopy), thereby helping to identify metabolites in biological samples [21, 43, 44, 48].
5.1.4. Bioinformatics
In NMR metabolomics, the interpretation and classification of the complex metabolic data sets
typically require the use of chemometric and pattern recognition (PR) techniques, and related
bio‐informatics tools. Pattern recognition techniques such as principal component analysis
(PCA) allow for the analysis and classification of the large number of complex NMR spectro‐
scopic data usually acquired for metabolic profiling of biological samples [44, 47, 48].
5.1.5. Applications of NMR–based metabolomics
NMR‐metabolomics has been applied to monitor cellular and systemic metabolic fluctuations
in response to xenobiotic exposure, environmental factors, physiological stimuli and genetic
modifications [21, 43–48]. Many applications of NMR‐metabolomics have been published,
including the extensive study of physiological variation in experimental animals, age‐related
changes, dietary modulation, diurnal effects and phenotyping of mutant and transgenic
animals [44, 47, 49].
NMR‐based metabolomics has found many applications in metabolic analysis of a wide
diversity of biological samples and has been recently used for characterization, monitoring
and optimisation of stem cell culture medium preparation [50]. NMR spectroscopy was used
for metabolomics analysis of human embryonic stem cell (hESCs) conditioning medium
characterization. A number of metabolites were identified and quantified in conditioned
media. Significantly, higher concentrations for certain metabolites (lactate, alanine, glutamine,
glucose and formate) and lower for others (tryptophan, folate and niacinamide) were detected
in the conditioned media compared to unconditioned media. Multivariate statistical analysis
was applied to classify the data and assess the main metabolic changes in the process of cell
conditioning. It was confirmed that NMR could be an accurate and valuable tool for monitor‐
ing, controlling and optimising hESC culture medium preparation. In this study, the detailed
scrutiny of metabolites involved in a variety of biochemical pathways for potential tissue
engineering applications has been facilitated [50].
In a more recent study by the application of proton NMR spectroscopy and implementation
of appropriate one‐dimensional (1D) and two‐dimensional (2D) NMR techniques, it was
confirmed that the metabolic composition of Wharton's jellies derived MSCs’ conditioned
media and changes in the metabolic profile of the culture media in the process of stem cell
expansion and differentiation. These changes were found to be affected mainly by the type of
the culture media and the duration of the conditioning time [31]. Typical 1H NMR spectra of
two different types of unconditioned and MSCs’ conditioned media are presented in Figure 5.
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Figure 5. Typical 600 MHz 1H NMR spectra recorded in H2O:D2O (9:1) of (A) Unconditioned medium I, (B) MSCs’ con‐
ditioned medium I; (C) Unconditioned medium II, (D) MSCs’ conditioned medium II. Characteristic signals of metabo‐
lites in the samples are marked.
Figure 6. Representative 2D NMR experiments of MSCs’ conditioned medium (conditioned medium I): (A) 1H/1H CO‐
SY spectrum, (B) 1H/1H TOCSY spectrum, (C) 1H/13C HSQC Spectrum.
The metabolomics study of different types culture media and the corresponding Wharton's
jelly derived MSCs’ conditioned media isolated at different time points was based on 1H NMR
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spectroscopy. Sodium trimethylsilyl‐[2,2,3,3‐d4]‐propionate (TSP) was used as an internal
reference for the calibration and quantification of NMR spectra. 1H NMR spectra with
suppression of the water resonance signal using a 1D NOESY and CPMG pulse sequences were
acquired. The NMR spectra were acquired and processed uniformly using TOPSPIN 3.2
(Bruker Biospin).
Additionally, to confirm the chemical shift assignment of 1H NMR spectra and facilitate the
identification of metabolites presented in both unconditioned and MSCs’ conditioned media,
the studied 2D 1H/1H COSY, 1H/1H TOCSY and 1H/13C HSQC spectra were obtained and
analysed (Figure 6). The results have been compared to the data published in the literature [51].
Metabolites Abbr. Chemical shifts (ppm); multiplicity
Isoleucine Ile 0.95(dd, δCH3), 1.27/1.46(m, γCH2), 1.98(m, βCH), 1.01(d, βCH3), 3.67(d, αCH)
Leucine Leu 0.95(d, δCH3), 0.97(d, δ'CH3), 1.69(m, γCH), 1.71(m, βCH2), 3.73(d, αCH)
Valine Val 0.98(d, γCH3), 1.05(d, γ'CH3), 2.27(m, βCH2), 3.61(d, αCH)
Ethanol Et 1.19 (t, CH3), 3.57 (q, CH2)
Threonine Thr 1.33(d, γCH3), 4.25(m, βCH2), 3.56(d, αCH)
Lactate Lac 1.34(d, βCH3), 4.13(q, αCH)
Alanine Ala 1.48(d, βCH3), 3.78(q, αCH)
Lysine Lys 3.04(t, εCH2), 1.73(m, δCH2), 1.47(m, γCH2), 1.93(m, βCH2), 3.77(t, αCH)
Arginine Arg 3.23(t, δCH2), 1.67(m, γCH2), 1.89(m, βCH2), 3.77(t, αCH)
Acetate Ace 1.92(s, CH3)
Glutamate Glu 2.36(t, γCH2), 2.08(m, βCH2), 3.74 (dd, αCH)
Glutamine Gln 2.44(t, γCH2), 2.51/2.04(m, βCH2), 3.76(dd, αCH)
Methionine Meth 2.2(s, δCH3), 2.45(m, γCH2), 2.13(m, βCH2), 3.75(t, αCH)
Choline Cho 3.19(s, CH3), 3.51(dd, CH2), 4.06 (dd, CH2),
Pyruvate CH3 2.39 (s)
α‐Glucose α‐Glu 5.24(d,H1),3.54(dd,H2),3.72(t,H3),3.41(t,H4), 3.47(dd,H5),3.91/3,72(dd, H6)
β‐Glucose β‐Glu 4.65(d,H1),3.24(t,H2),3.49(t,H3), 3.42(t,H4), 3.84(m,H5,6), 3.78(dd,H6)
Tyrosine Tyr 3.05/3.18 (βCH2), 3.93 (αCH), 7.19(d, H2,6), 6.90(d, H3,5)
Phenylalanine PheAla  3.12/3.26 (βCH2), 3.97 (αCH), 7.33(d, H2,6), 7.38(t,H4), 7.43(t, H3,5)
Histidine His 3.12/3.22 (βCH2), 3.97 (αCH), 7.75(s, H2), 7.05(s, H5)
Tryptophan Try 3.29/3.47 (βCH2), 4.05 (αCH), 7.30 (H2), 7.74(d, H4), 7.20(t, H5), 7.28(t, H6), 7.55(d, H7)
Nicotinamide NA 7.58 (dd, CH), 8.24 (dd, CH), 8.70 (dd, CH), 8.94 (s, CH)
Formate For 8.46 (CH)
Table 1. 1H NMR chemical shifts and multiplicity of the main metabolites observed in the spectra of culture medium
and MSCs’ secretome.
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From the analysis of the 1H and 2D (1H/1H homonuclear and 1H, 13C heteronuclear correlation
spectra) NMR spectra, certain number of metabolites have been identified. The main metab‐
olites identified in the samples are listed in Table 1 with an assignment of the corresponding
resonance signals and their multiplicity in 1H NMR spectra recorded.
Figure 7. (A) Relative distribution (%) of the main metabolites detected in the culture media I and II and the corre‐
sponding MSCs’ conditioned media I and II [31]; (B) Relative distribution (%) of the main metabolites detected in the
culture media I and II and the corresponding MSCs’ conditioned media I and II, and umbilical cord blood plasma
(hUCBP) [31]; (C) Typical 600 MHz 1H NMR spectra recorded in H2O:D2O (9:1) of two plasma samples obtained from
umbilical cord blood (hUCBP) and foetal bovine serum (FBS) from three different manufacturers; (D) The quantitative
distribution (ppm) of metabolites determined from the integral intensity of characteristic signals in 1H NMR spectra
considering the number of protons contributing to the intensity of the signal in umbilical cord blood plasma (hUCBP)
and foetal bovine serum (SBF) from two different fabricants used of in vitro culture of MSCs from the umbilical cord
matrix (MSCs_SBF) and dental pulp mesenchymal stem cells (DPSCs_SBF).
The metabolite content in two different types of culture media (culture media I and II) and the
corresponding Wharton's jelly derived MSCs’ conditioned media collected at different time
points was defined by quantitative NMR analysis, using the relative quantitative method [52].
The quantitative distribution of the NMR‐visible metabolites was determined from the relative
integral intensity of characteristic signals in 1H NMR spectra of the samples referenced to the
integral intensity of TSP (internal standard), considering the number of the contributing nuclei
for that particular resonance. The relative quantitative distribution of the main metabolites
detected in the 1H NMR spectra of the two different types of culture media (culture medium
I and culture medium II) and the corresponding Wharton's jelly derived MSCs’ conditioned
media collected after 24 h of conditioning is presented graphically in Figure 7A.
The results from the NMR metabolomics analysis reveal the presence of important amino acids,
glucose and low molecular weight (lactate, acetate, pyruvate and formate) compounds in the
basal culture media (types I and II) and the corresponding conditioned media.
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Different contents of glucose, lactate and certain amino acids were detected in the two basal
culture media (types I and II) and the corresponding conditioned media (Figures 3 and 7A).
Gathering the results of unconditioned media (types I and II) and comparing them globally
with the corresponding conditioned media, it is possible to attest not only to metabolite
depletion through cell metabolisation (as the glucose example), but also to some metabolites
(like lactate, isoleucine, leucine, valine, arginine, lysine, glutamate, formate or pyruvate)
presented in higher concentration, reflecting the production and secretion of metabolites.
Metabolic differences between samples collected at different time points (24 and 48 h) were
also considered [31]. This is because conditioned media could be achieved at different stages
after reaching minimal cell confluence.
5.2. Metabolic analysis of hUCBP by NMR spectroscopy
The metabolite profiles of the unconditioned and MSCs’ conditioned media (types I and II)
were further compared with those of human umbilical cord blood plasma (hUCBP) (Fig‐
ure 7B) which has been considered as a promising culture medium supplement due to the fact
that UCB is rich in soluble growth factors that support the growth, proliferation and differen‐
tiation of mesenchymal and hematopoietic stem cells [31, 33, 34].
The comparative study of the metabolic profiles of unconditioned media, MSCs’ conditioned
media and hUCBP reveals the presence of essential proteinogenic amino acids (alanine,
arginine, isoleucine, histidine, leucine, lysine, phenylalanine, proline, tyrosine, valine), organic
acids and derivatives (lactate, formate and creatine), glucose and nucleotides (adenosine,
uridine and guanosine species) in the last. The results strongly suggest that hUCBP might be
used as a culture medium supplement in the processes of cell isolation, expansion and
cryopreservation and even as an alternative in the cellular therapy [31]. Moreover, hUCBP
could be considered as an animal sera substituent that could solve important economic, ethical
and scientific issues that have severe complications in the utilization of foetal bovine serum
(FBS) for cell culture. In addition, hUCBP are attractive alternatives to FBS due to the world‐
wide increase in the number of cryopreserved UCB units in Public and Private Cord Blood
Banks. However, the substitute medium supplement must possess the animal sera character‐
istics crucial for the cell expansion and preservation.
Recently, a comparative study of the metabolic composition of hUCBP and FBS, based on 1H
NMR spectroscopy and multivariate statistical analysis has been performed to evaluate the
capability of hUCBP as a culture medium supplement and FBS substituent for in vitro
proliferation and cryopreservation of MSCs. Figure 7C shows typical 1H NMR spectra of
hUCBP and FBS.
However, 1D and 2D NMR techniques have been used to identify and quantify the detectible
metabolites in the samples. The quantitative distribution of metabolites presented in Figure 7D
was determined from the integral intensity of characteristic signals in 1H NMR spectra
considering the number of protons contributing to the intensity of the signal.
The results show that the differences between the metabolic composition of hUCBP and FBS
are due mainly to the different content of glucose, lactate, acetate, glutamate and alanine. The
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much higher content of glucose determined for hUCBP has been attributed to the UCB function
to provide energetic support for the foetus during intrauterine development. From the analysis
of the NMR spectra it was confirmed the presence of essential proteinogenic amino acids such
as alanine, arginine, creatine, glutamine, glutamate, isoleucine, histidine, leucine, lysine,
phenylalanine, proline, threonine, tyrosine and valine in hUBCP as well as in FBS. These
proteinogenic amino acids are precursors to proteins and could play a crucial role in the
growth, proliferation and differentiation of cells. Significantly, higher levels of alanine,
glutamate, isoleucine, leucine and valine in the commercial FBS as compared to hUBCP are
determined. This seems to be the main difference between the amino acids profiles of human
UBC plasma and foetal bovine sera. The increased levels of alanine and glutamine could due
to the use of supplements such as Glutamax® in the commercial FBS sera [50]. Similar or slightly
higher contents of arginine, citrulline, creatine, histidine, lysine, phenylalanine and tyrosine,
nucleotides and lipids were found in hUBCP as compared to the FBS samples studied.
Figure 8. A and B—PCA statistics. PCs distribution of NMR data matrix (A) and Score plots (PC1 versus PC2) (B) and
—PC1 and PC2 loading plots (C).
Principal component analysis has been used to interpret and classify the NMR spectral data
obtained for a certain number of hUCBP (samples of 11 donors) and FBS samples (MSCs_FBS
(3 samples of MSCs FBS and three samples of DPSCS FBS) to evaluate the main factors
contributing to the discrimination between the two groups of samples.
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The contributions of the principal components (PCs) of the NMR spectral data are depicted in
Figure 8A and B. The first two PCs accumulate more than 85 % of data variance. Therefore
statistical analysis based on PC1 and PC2 is legitimate.
The 2D (PC1 versus PC2) PCA score plot is depicted in Figure 8B. The results illustrate the
close similarity of MSCs_FBS and DPSCS_FBS data sets (a well‐defined cluster with overlap‐
ping samples) and reveal their separation from the human plasma data (a scattered cluster).
The corresponding loading plots in Figure 8C provide evidence that the glucose, lactate and
acetates are the metabolites contributing to the divergence between the human plasma and
FBS data sets. The results also reveal the close content of essential proteinogenic amino acids
in the human plasma and foetal bovine sera. Loading plots around zero line suggest close
metabolic profiles in the spectral region from 9.0 to 5.3 ppm of the three groups.
6. Conclusions
In brief conclusion, proteomic and metabolomics studies have demonstrated the richness of
MSC’ conditioned medium in terms of growth factors with in situ action in disease and
regeneration processes, as well as in other metabolites that interact with the environment
surrounding the mesenchymal cellular populations. Hence, as knowledge is gained in its
composition and potential, thought these omics techniques and other assays, their potential
on the application for the treatment of number of diseases increases alike.
As for the hUCBP, given its similarity and even superiority (in supplementary proteins and
other contents) to promote and sustain MSCs’ expansion, it might become a standardized
human derived supplement for cellular populations aiming at the production of secretome or
direct application in effective clinical treatments.
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